Y-mAbs Therapeutics (NASDAQ:YMAB) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report released on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $20.00 target price on the stock.

Several other research firms also recently weighed in on YMAB. HC Wainwright reiterated a buy rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. BMO Capital Markets lowered their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an outperform rating on the stock in a research note on Tuesday, August 13th. Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an underweight rating for the company in a report on Tuesday, August 13th. Wedbush reissued an outperform rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, August 12th. Finally, Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a report on Friday, June 28th. They issued a buy rating and a $21.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $21.14.

Y-mAbs Therapeutics Stock Down 1.0 %

YMAB stock opened at $13.27 on Monday. Y-mAbs Therapeutics has a 12-month low of $4.69 and a 12-month high of $20.90. The firm has a market cap of $591.44 million, a PE ratio of -27.08 and a beta of 0.70. The business has a 50 day moving average of $12.54 and a 200-day moving average of $13.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $22.80 million during the quarter, compared to the consensus estimate of $23.09 million. During the same quarter in the previous year, the firm earned ($0.14) earnings per share. On average, research analysts expect that Y-mAbs Therapeutics will post -0.57 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In related news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 21.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in YMAB. Campbell & CO Investment Adviser LLC bought a new stake in Y-mAbs Therapeutics in the fourth quarter worth $562,000. Squarepoint Ops LLC boosted its stake in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares in the last quarter. Millennium Management LLC grew its position in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares in the last quarter. Finally, Boston Partners purchased a new position in Y-mAbs Therapeutics in the first quarter worth about $556,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.